retinai.comCrawled Nov 12, 2026
RetinAI’s Disease Evaluation Apps for OCT, Fundus and others are accessed via Heidelberg AppWay. AppWay is a secure data transfer portal integrated in Heidelberg’s HEYEX 2.6. The Disease Apps provide expert-level analysis of a patient’s OCT volumes.
RetinAI Discovery aggregates medical images and data via PACS or API for AI-driven insights on diseases and outcomes.
RetinAI has certified AI solutions that provide automated analysis across disparate imaging datasets. Clinics can continue to use the imaging platforms they prefer, while benefiting from enhanced imaging capabilities for accelerating clinical studies, choosing treatments or monitoring outcomes.
RetinAI Discovery processes images, EHR, demographics, and genetic data to analyze patient populations at scale.
The newsletter covers ophthalmology trends, RetinAI products, and services.
Resources support RetinAI’s products and services.
The BETTER study - Learn about a new Case Study for RetinAI Discovery for Clinical Studies.
RetinAI, a Bern-based company, raised CHF 2.3 million in pre-Series A funding led by btov Partners.
Brand materials and media information are available here.
The news section updates RetinAI developments.
RetinAI’s disease evaluation apps for OCT and Fundus require a Heidelberg AppWay account for expert analysis.
RetinAI resources.
Get to know RetinAI's Leadership, Board of Directors and Scientific Advisors.
RetinAI follows ISO, FDA, and MDR standards for performance and care.
Contact RetinAI for inquiries about the company or its products and services.
RetinAI develops solutions to generate and organize insights and knowledge to improve patient outcomes.
The privacy notice explains how RetinAI handles third-party information.
Welcome to the RetinAI Apps Terms & Conditions of Use.
